An exploratory phase II trial of bemarituzumab (NCT03694522) in HER2-negative gastroesophageal junction adenocarcinomas and gastric cancer promising clinical efficacy was reported despite no statistically significant improvement in progression-free survival [87]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.